NCRI Press Release, 9 November 2016
Date published: Apr 03 2018
Marker for aggressive prostate cancer doubles-up as a drug target
Download the attachmentRecent Tweets
-
Could #radiotherapy disrupt the blood-brain barrier and help treat #BrainMetastasis? The #CamBMT1 study is looking… https://t.co/RXmfB3kqij
2 days ago -
#CamBMT1 PI @Richard_Baird received support from the @NCRI_partners #Lung_Group, #Breast_Group, #Brain_Group and… https://t.co/wLhsvRoJDV
2 days ago -
The #CamBMT1 study is looking at whether combining drug treatment with targeted radiotherapy could improve prognosi… https://t.co/7y42li3mvv
2 days ago
- 19 Mar 2020Workstream leads: NCRI Skin Group
- 26 Nov 2019CM-Path - Application for Consumer Membership (Deadline - 1st January 2020)
- 20 Nov 2019With its new chair, Professor David Harrison, at the helm, CM-Path share top priorities
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed